Disease · MONDO_0020654

renal pelvis/ureter urothelial carcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. renal pelvis/ureter urothelial carcinoma. Diseases, record MONDO_0020654. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0020654

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: renal pelvis/ureter urothelial carcinoma; Open Targets
Open Targets ID: MONDO_0020654; Open Targets
Other names: TCC of renal pelvis and ureter, TCC of the renal pelvis and ureter, UTUC, renal pelvis and ureter TCC, renal pelvis and ureter transitional cell cancer, renal pelvis and ureter transitional cell carcinoma, renal pelvis and ureter urothelial carcinoma, transitional cell cancer of renal pelvis and ureter, transitional cell cancer of the renal pelvis and ureter, transitional cell carcinoma of renal pelvis and ureter, transitional cell carcinoma of the pelvis and ureter, transitional cell carcinoma of the upper urinary tract, upper tract urothelial carcinoma, urothelial carcinoma of the renal pelvis and ureter; Open Targets
NCI Thesaurus: C7716; NCI Thesaurus
Orphanet: ORPHA:598216; Orphanet
Highest stage of its drugs: Phase 3, for 2 of its 19 drugs, from ClinicalTrials.gov; Open Targets

Drugs19

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
MITOMYCIN	CHEMBL105	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
PADELIPORFIN	CHEMBL4594284	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
GEMCITABINE	CHEMBL888	Small molecule	Phase 2	ClinicalTrials.gov	7	7	7	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 2	ClinicalTrials.gov	6	6	6	Drugs and targets
TISLELIZUMAB	CHEMBL4297840	Antibody	Phase 2	ClinicalTrials.gov	6	6	5	Drugs and targets
DISITAMAB VEDOTIN	CHEMBL5095273	Antibody drug conjugate	Phase 2	ClinicalTrials.gov	5	5	5	Drugs and targets
AVELUMAB	CHEMBL3833373	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
BCG LIVE	CHEMBL2108020		Phase 2	ClinicalTrials.gov	1	1	0	Drugs and targets
BCG VACCINE	CHEMBL2108905	Vaccine component	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
BULUMTATUG FUVEDOTIN	CHEMBL6068217	Antibody	Phase 2	ClinicalTrials.gov	1	1	0	Drugs and targets

1 to 10 of 19

See all 19 drugs

Targets38

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PDCD1	Programmed cell death protein 1	4	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 2	https://conductscience.org/library/genes/5133	Drugs and targets
POLA1	DNA polymerase (alpha/delta/epsilon)	2	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 2	https://conductscience.org/library/genes/5422	Drugs and targets
POLA2	DNA polymerase (alpha/delta/epsilon)	2	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 2	https://conductscience.org/library/genes/23649	Drugs and targets
POLD1	DNA polymerase (alpha/delta/epsilon)	2	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 2	https://conductscience.org/library/genes/5424	Drugs and targets
POLD2	DNA polymerase (alpha/delta/epsilon)	2	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 2	https://conductscience.org/library/genes/5425	Drugs and targets
POLD3	DNA polymerase (alpha/delta/epsilon)	2	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 2	https://conductscience.org/library/genes/10714	Drugs and targets
POLD4	DNA polymerase (alpha/delta/epsilon)	2	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 2	https://conductscience.org/library/genes/57804	Drugs and targets
POLE	DNA polymerase (alpha/delta/epsilon)	2	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 2	https://conductscience.org/library/genes/5426	Drugs and targets
POLE2	DNA polymerase (alpha/delta/epsilon)	2	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 2	https://conductscience.org/library/genes/5427	Drugs and targets
POLE3	DNA polymerase (alpha/delta/epsilon)	2	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 2	https://conductscience.org/library/genes/54107	Drugs and targets

1 to 10 of 38

See all 38 targets

Trials25

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02793128	The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study	Phase 3	71	2020-11-20	Carcinoma, Transitional Cell, Transitional Cell Carcinoma of Renal Pelvis	MITOMYCIN	Its record names the disease	ClinicalTrials.gov
NCT04228042	Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial Cancer	Phase 1/2	15	2025-01-01	Renal Pelvis and Ureter Urothelial Carcinoma	INFIGRATINIB	Its record names the disease	ClinicalTrials.gov
NCT04871529	Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)	Phase 2	6	2024-12-30	Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Infiltrating Renal Pelvis and Ureter Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8	AVELUMAB, CARBOPLATIN, GEMCITABINE HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT01663285	Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC)	Phase 2	1	2014-09-18	Urothelial Cancer, Bladder Cancer	CISPLATIN, GEMCITABINE	Its record names the disease	ClinicalTrials.gov
NCT06167057	POST URS Chemotherapy Instillation	Not applicable	264		UTUC	GEMCITABINE, MITOMYCIN	Its record names the disease	ClinicalTrials.gov
NCT07498907	Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma	Phase 3	192		Upper Tract Urothelial Carcinoma	DISITAMAB VEDOTIN	Its record names the disease	ClinicalTrials.gov
NCT07155044	A Comparative Study of Neoadjuvant Chemotherapy Versus Upfront Radical Surgery for Upper Tract Urothelial Carcinoma		120		UTUC, UC (Urothelial Cancer)	CISPLATIN, GEMCITABINE	Its record names the disease	ClinicalTrials.gov
NCT07492225	Neoadjuvant Chemotherapy Before Surgery vs Surgery Alone for UTUC: A Randomized Trial	Phase 2	120		Neoadjuvant Therapy, Urothelial Carcinoma Ureter, Upper Urinary Tract Urothelial Carcinoma	CISPLATIN, GEMCITABINE	Its record names the disease	ClinicalTrials.gov
NCT04620239	ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study	Phase 3	89		Transitional Cell Cancer of Renal Pelvis and Ureter	PADELIPORFIN	Its record names the disease	ClinicalTrials.gov
NCT02876861	Neoadjuvant Chemotherapy Versus Surgery Alone in Patients With High-Grade UTUC	Phase 2	74		High-Grade Upper Tract Urothelial Carcinoma	CISPLATIN, GEMCITABINE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 25

See all 25 trials

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Gemcitabine + Carboplatin + Avelumab + Surgery vs Surgery Only: deaths from any cause	0 of 2	1 of 1	3	NCT04871529	Trial comparisons
Gemcitabine + Carboplatin + Avelumab + Surgery vs Surgery Only: serious adverse events	0 of 2	0 of 1	3	NCT04871529	Trial comparisons

Papers from its trials9

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
39999445	DERIVED	1	PubMed
39561384	DERIVED	1	PubMed
38573872	DERIVED	1	PubMed
36603175	DERIVED	1	PubMed
33677615	DERIVED	1	PubMed
33168398	DERIVED	1	PubMed
32670424	DERIVED	1	PubMed
32631491	DERIVED	1	PubMed
31796469	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0020654

GET https://conductscience.org/api/diseases/v1/MONDO_0020654/targets?page=2

API reference For AI assistants